Last update: Jan. 14, 2019
Minimal risk for breastfeeding and infant.
It is an alpha-1-adrenergic blocking agent that is used for treatment of arterial hypertension and of obstructive symptoms resulting from benign prostatic hypertrophy.
Oral administration once a day.
Its pharmacokinetic data (moderately elevated molecular weight, high percentage of plasma protein binding and high volume of distribution) (Pfizer 2017, Kirsten 1998, Elliot 1987) probably explain the negligible excretion observed in milk (Pfizer 2017, Versmissen 2016, Jensen 2013 y 2014).
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug may be used (Anderson 2018, Schaefer 2007 p685), especially during the neonatal period and/or in case of premature infants.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM